SHEFFIELD, England--(BUSINESS WIRE)--With China poised to become the world’s third largest market for pharmaceuticals, Simcyp Limited today announces the addition of a virtual Chinese patient population to the portfolio of virtual human populations within the Simcyp Simulator – the industry’s most sophisticated tool for the simulation of drug-drug interactions and pharmacokinetic outcomes.
